⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GHRS News
GH Research PLC Ordinary Shares
A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
prnewswire.com
GHRS
HELP
DFTX
JNJ
CMPS
Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
prnewswire.com
GHRS
HELP
DFTX
ATAI
CMPS
LLY
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
globenewswire.com
HELP
DFTX
CMPS
GHRS
JNJ
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
prnewswire.com
GHRS
HELP
DFTX
CMPS
GH Research Announces Publication of Phase 2a Postpartum Depression Results
globenewswire.com
GHRS
GH Research Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com
GHRS
GH Research Announces Pricing of $117.5 Million Underwritten Offering
globenewswire.com
GHRS
GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness
globenewswire.com
GHRS
GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
globenewswire.com
GHRS
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions
prnewswire.com
GHRS
HELP
DFTX
ATAI
CMPS